All In MedTech

Device Trial Radar · NCT03323554

Safety and Efficacy Study of USTRAP™ in Male Urinary Incontinence

Prospective Interventional Safety and Efficacy Study of USTRAP™ in Male Urinary Incontinence. an Open, Randomised, Multicentre Study Versus Artificial Sphincter.

Last checked: Nov 20, 2026Latest source record: Mar 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

20

Actual

Start

Jun 1, 2018

Primary completion

Dec 1, 2026

Study completion Dec 1, 2026

Sponsor

Lead sponsor
Quanta MedicalNot on our public-company list
Sponsor type
Industry
Collaborators
Cousin Biotech
First posted
Oct 27, 2017

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Few surgical methods to treat male stress urinary incontinence have been assessed in comparative, randomised interventional studies. Ustrap is a new adjustable-pressure 4-arm device. The artificial sphincter is currently considered the gold standard device in this field. The aim of this randomised prospective international study is to assess the efficacy and safety of the Ustrap® device comparatively with an artificial sphincter (AMS800) in the treatment of stress urinary incontinence following prostate removal in cancer patients.

Conditions

  • Urinary Incontinence

Interventions

  • Ustrap®Device

    Patients will receive Ustrap® under general or loco-regional anaesthesia, by perineal approach.

  • AMS 800®Device

    Patients will receive AMS 800® under general or loco-regional anaesthesia. Small openings are made near the scrotum and below the abdomen to insert an inflatable cuff, a pump and a small balloon (pressure regulating balloon).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. comparison of succes rateTime frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CHU Charles Nicolle

    Rouen, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.